What do Chinese investigators, reviewers really want?
This article was originally published in Scrip
You may also be interested in...
CanSino plans to start a Phase III study soon for its candidate with a 40,000 enrollment target, discloses its co-founder.
Biogen/Eisai’s US filing of aducanumab for Alzheimer’s has a ripple effect in China, where a leading biomedical researcher has publicly questioned data for the country’s first approved drug for the disease, GV971.
From cell therapy to digital health, from fast follower to innovator, China continues to gain traction with global health companies, underscored by its early emergence from the global pandemic and focus on certain technologies, with Boehringer Ingelheim the latest to be attracted.